Melasma
☆ Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
40 urte hasieran dituzten asiar emakumeetan ikusten den egoera arrunta da. Argazkian inguratutako lesioa lentigotik gertuago dago melasmatik baino.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Duela gutxi, low-fluence Q-switched Nd:YAG (LFQSNY) laser melasma tratatzeko ezaguna bihurtu da, batez ere Asian. Hainbat ikerketak laburtzea zaila izan zen, baina LFQSNY, oro har, eraginkorra eta segurua dirudi melasmarentzat terapia tradizionalekin alderatuta. Hala ere, hipopigmentazio moteduaren kasu batzuk LFQSNYren albo-ondorio gisa jakinarazi dira, ziurrenik laser energia handia dela eta. LFQSNYren erabilera oldarkorrak hanturaren hiperpigmentazioa ere ekar dezake, batez ere larruazaleko tonu ilunetan.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Pigmentazio-arazoak lehen mailako arretan aurkitu ohi dira. Hiperpigmentazio-nahaste mota arruntak post-inflammatory hyperpigmentation, melasma, sunspots, freckles, and café au lait spots dira.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma ezin da laser tratamenduarekin konpondu denbora tarte jakin batean, pigmentua etengabe sortzen den gaixotasuna baita. Azido tranxenemikoak pigmentazioa murrizten laguntzen du.
○ Tratamendua
Zenbait herrialdetan (adibidez, Japonian, Korea), ahozko azido tranexamikoa mostradorean eskuragarri dago eta eraginkorra da. Azido tranexamikoarekin eta azido azelaikoarekin melasma krema partzialki lagungarria izan daiteke.
Hidrokinona topikoki erabil daiteke hiperpigmentazioa tratatzeko, baina FDAk hidrokinona zuten OTC produktuak gelditu zituen 2020tik aurrera.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma